Literature DB >> 8473173

[Mirizzi syndrome--a contraindication for laparoscopic surgery].

J J Moser1, H U Baer, A Glättli, W Schweizer, L H Blumgart, A Czerniak.   

Abstract

The Mirizzi syndrome refers to a benign obstruction of the common hepatic duct by a stone impacted within the cystic duct or the neck of the gallbladder causing an obstructive jaundice. According to McSherry's subclassification based on endoscopic retrograde cholangio-pancreatography we distinguish a type I, involving an external compression of the common hepatic duct by a large stone impacted in the cystic duct or Hartmann's pouch without lesion of the gallbladder or the common hepatic duct wall. In type II a cholecysto-choledochal fistula is present, caused by a calculous which has already eroded partly or completely into the common bile duct. The type I is better treated with a partial cholecystectomy, the type II with a partial cholecystectomy and a bilio-digestive anastomosis. Due to a severe inflammatory process with dense adhesions and odematous changes of the hepato-duodenal ligament, it is dangerous to prepare the Calot's triangle, in case of conventional cholecystectomy and/or in case of laparoscopic cholecystectomy. From 1986-1991 we have successfully treated 10 patients according to this concept (7 patients with type II, 3 patients with type I). We have no mortality and no lesion of the biliary system. One patient has been reoperated because of a postoperative hemorrhage and biliary fistula. One patient developed a benign stricture which could be dilated two months after the procedure. Two patients were found with an incidental carcinoma of the gallbladder.

Entities:  

Mesh:

Year:  1993        PMID: 8473173

Source DB:  PubMed          Journal:  Helv Chir Acta        ISSN: 0018-0181


  2 in total

1.  Mirizzi syndrome.

Authors:  Pv Rama Mohan; M Kumar; R Pacharu
Journal:  Med J Armed Forces India       Date:  2011-08-07

2.  A clinicopathological analysis in unsuspected gallbladder carcinoma: a report of 23 cases.

Authors:  Li-Ning Xu; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.